Rasagiline mesylate is used to treat Parkinson’s disease, either alone or with levodopa. It works by inhibiting MAO-B, increasing dopamine levels in the brain. This helps reduce motor symptoms like tremor, stiffness, and “off” episodes. It may also have potential neuroprotective effects, though not clinically confirmed. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Azilect, Agilect and Rasagiline methanesulfonate. Its PubChem CID is 3052775.
Rasagiline mesylate
| CAS No | 161735-79-1 |
|---|---|
| Molecular Formula | C13H17NO3S |
| Molecular Weight | 267.35 g/mol |
| Synonyms | methanesulfonic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rasagiline mesylate is used to treat Parkinson’s disease, either alone or with levodopa. It works by inhibiting MAO-B, increasing dopamine levels in the brain. This helps reduce motor symptoms like tremor, stiffness, and "off" episodes.
The listed CAS number is 161735-79-1.
The listed molecular formula is C13H17NO3S.
The listed molecular weight is 267.35 g/mol.
methanesulfonic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine.
The source lists Azilect, Agilect and Rasagiline methanesulfonate.